Research programme: age-related macular degeneration therapy - Medigene AG

Drug Profile

Research programme: age-related macular degeneration therapy - Medigene AG

Alternative Names: EndoGreen

Latest Information Update: 30 Aug 2010

Price : $50

At a glance

  • Originator MediGene AG
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Age-related macular degeneration

Most Recent Events

  • 15 Mar 2007 Preclinical trials in Age-related macular degeneration in Germany (unspecified route)
  • 15 Mar 2007 EndoGreen is available for licensing worldwide (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top